Press release
Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2024 - By Share, Top Companies, Revenue Outlook And Growth Forecast By 2033
Duchenne Muscular Dystrophy (DMD) Therapeutics Market
As per the report, the duchenne muscular dystrophy (dmd) therapeutics market size has grown exponentially in recent years. It will grow from $8.64 billion in 2023 to $11.95 billion in 2024 at a compound annual growth rate (CAGR) of 38.4%. The duchenne muscular dystrophy (dmd) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $36.72 billion in 2028 at a compound annual growth rate (CAGR) of 32.4%.
Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12916&type=smp
Increasing Clinical Trials Revolutionize The Duchenne Muscular Dystrophy (DMD) Therapeutics Market
The rising number of clinical trials is expected to propel the growth of the Duchenne muscular dystrophy (DMD) therapeutics market going forward. Clinical trials are research studies conducted on human participants to evaluate the safety, efficacy and potential benefits of new medical treatments, interventions, or drugs. The surge in clinical trials focusing on Duchenne muscular dystrophy treatment signifies continuous research, innovation and a wide array of therapeutic possibilities, all of which are expected to enhance patient outcomes, attract investments and expedite the advancement and Availability of Effective Therapies for Duchenne Muscular Dystrophy (DMD). For Instance, In August 2023, according to Clinicaltrials.Gov, a part of The National Institutes Of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, the number of registered clinical trials increased to 464,218 compared to 399,496 in 2021 in all 50 states of the United States and across 221 countries. Moreover, it was reported that 142,700 studies (31% of the total) are registered in the U.S., while 248,310 studies (53% of the total) are recorded in non-U.S. locations. Therefore, a rising number of clinical trials will drive the growth of the duchenne muscular dystrophy (DMD) therapeutics market.
Bit Bio Leads Technological Advancements In Duchenne Muscular Dystrophy (DMD) Therapeutics
Major companies operating in the duchenne muscular dystrophy (DMD) therapeutics market are adopting new technologies to enhance the efficacy and accessibility of treatments for DMD patients and sustain their position in the market. For instance, in July 2023, Bit Bio Ltd., a UK-based synthetic biology company, launched disease model products to advance Duchenne muscular dystrophy (DMD) treatments. The disease models, known as ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, are human skeletal myocytes carrying genetically engineered deletions in the gene responsible for dystrophin protein production. Bit. Bio's models, reprogrammed from induced pluripotent stem cells (iPSCs), provide a consistent and scalable source of human cells for research, addressing challenges associated with variability and the sourcing of primary cells. The models support the development of treatments for DMD, offering insights into disease mechanisms and potential therapies. This advancement could accelerate the work of researchers seeking effective treatments for DMD.
The duchenne muscular dystrophy (dmd) therapeutics market covered in this report is segmented -
1) By Type: Small Molecules; Biologics
2) By Distribution Channel: Offline; Online
3) By Application: Hospitals; Clinics; Home Care
Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12916&type=discount
Major players in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings PLC, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.
Contents of the report:
1. Executive Summary
2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report Structure
3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends And Strategies
4. Duchenne Muscular Dystrophy (DMD) Therapeutics Market - Macro Economic Scenario
5. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size And Growth
…..
27. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-dmd-therapeutics-global-market-report
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2024 - By Share, Top Companies, Revenue Outlook And Growth Forecast By 2033 here
News-ID: 3618589 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for DMD
Duchenne Muscular Dystrophy (DMD) Market Growth in 2034
Market Overview
The Duchenne Muscular Dystrophy (DMD) Market is expanding rapidly as advances in genetic medicine, exon-skipping therapies, gene therapy platforms, and improved diagnostic capabilities reshape treatment options for this severe, progressive neuromuscular disorder.
DMD is caused by mutations in the dystrophin gene, leading to muscle degeneration beginning in early childhood. Growing awareness among clinicians and caregivers, widespread adoption of next-generation sequencing (NGS), and increasing availability of disease-modifying therapies have significantly strengthened…
Emerging Trends to Reshape the Duchenne Muscular Dystrophy (DMD) Therapeutics Ma …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for duchenne muscular dystrophy (DMD) therapeutics has seen a significant increase in the recent years. The market, which was valued at $11.95 billion in 2024, is anticipated to expand…
Emerging Trends Influencing The Growth Of The Duchenne Muscular Dystrophy (DMD) …
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Expected to Be by 2034?
In recent times, the market size for Duchenne Muscular Dystrophy (DMD) therapeutics has seen a significant…
Leading Portland Dentist Michael P. Naughton, DMD, Unveils Magnolia Dental
Image: https://www.globalnewslines.com/uploads/2025/03/1741300210.jpg
Dr. Naughton is sharing the official new name of his renowned dental office, which provides premier dental services for the Portland, Oregon, region.
PORTLAND, OREGON - March 7th, 2025 - Michael P. Naughton, DMD, is excited to announce the official new name of his dental office. New and existing clients alike are now being greeted by Magnolia Dental [https://magnoliadentalpdx.com/], which offers the same office, staff, and exceptional level of dental…
Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market in 2025: Bit B …
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expected to Be, and What Will Its Growth Rate Be?
The Duchenne muscular dystrophy (DMD) therapeutics market will grow from $11.95 billion in 2024 to $16.45 billion in 2025, at a CAGR of 37.6%. The growth is attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness of treatment options, healthcare spending, and government initiatives.
The Duchenne muscular dystrophy (DMD) therapeutics…
Hershey Family Dentistry Rebrands Under Dr. William Svitko, DMD
Award nominee Dr. William Svitko has become a widely recognized and sought after dentist in the Hershey, PA, area.
Image: https://www.getnews.info/uploads/ca064454a8c76f46c800ec30173f7d6d.png
Progressive Dental Concepts (PDC) is excited to announce its rebranding of Wesley R Davis Family Dentistry to Hershey Family Dentistry (HFD), marking a new chapter in the practice's history under the leadership of Dr. William Svitko, DMD. The rebrand includes the launch of a new, user-friendly website, designed to enhance patient…
